EGFR and prostate cancer: The targeted toxin EGF-PE24mut showed high and specific cytotoxicity in EGFR-expressing prostate cancer cells, which was more than 600 to 3,000-fold cytotoxic than the EGFR inhibitor erlotinib 9.